JP2019526571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526571A5 JP2019526571A5 JP2019511720A JP2019511720A JP2019526571A5 JP 2019526571 A5 JP2019526571 A5 JP 2019526571A5 JP 2019511720 A JP2019511720 A JP 2019511720A JP 2019511720 A JP2019511720 A JP 2019511720A JP 2019526571 A5 JP2019526571 A5 JP 2019526571A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- composition according
- acid
- neurotransmission
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614834.8A GB201614834D0 (en) | 2016-09-01 | 2016-09-01 | Treatment of dementia |
| GB1614834.8 | 2016-09-01 | ||
| PCT/EP2017/071437 WO2018041739A1 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526571A JP2019526571A (ja) | 2019-09-19 |
| JP2019526571A5 true JP2019526571A5 (enExample) | 2020-10-01 |
| JP7066679B2 JP7066679B2 (ja) | 2022-05-13 |
Family
ID=57139937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511720A Active JP7066679B2 (ja) | 2016-09-01 | 2017-08-25 | 認知症の処置 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10842796B2 (enExample) |
| EP (1) | EP3506904B1 (enExample) |
| JP (1) | JP7066679B2 (enExample) |
| KR (1) | KR102559354B1 (enExample) |
| CN (1) | CN109890391B (enExample) |
| AU (1) | AU2017318333B2 (enExample) |
| CA (1) | CA3034625A1 (enExample) |
| DK (1) | DK3506904T3 (enExample) |
| ES (1) | ES2847929T3 (enExample) |
| GB (1) | GB201614834D0 (enExample) |
| HR (1) | HRP20210162T1 (enExample) |
| MX (1) | MX384442B (enExample) |
| MY (1) | MY187564A (enExample) |
| PL (1) | PL3506904T3 (enExample) |
| PT (1) | PT3506904T (enExample) |
| SG (1) | SG11201901125TA (enExample) |
| SI (1) | SI3506904T1 (enExample) |
| WO (1) | WO2018041739A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2013191E (pt) | 2006-03-29 | 2010-10-29 | Wista Lab Ltd | Sais de 3,7-diamino-10h-fenotiazina e a sua utilização |
| MY148145A (en) | 2006-07-11 | 2013-03-15 | Wista Lab Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| WO2018019823A1 (en) | 2016-07-25 | 2018-02-01 | Wista Laboratories Ltd. | Administration and dosage of diaminophenothiazines |
| SG11202100333XA (en) | 2018-07-26 | 2021-02-25 | Wista Lab Ltd | Optimised dosage of diaminophenothiazines in populations |
| KR102700017B1 (ko) | 2018-09-05 | 2024-08-29 | 젠팅 타우알엑스 다이어그노스틱 센터 에스디엔 비에이치디 | 신경퇴행성 질환에 대한 네트워크 방법 |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909454D0 (en) * | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| US20230158040A1 (en) * | 2020-05-05 | 2023-05-25 | Wista Laboratories Ltd. | Methylthioninium compounds for use in the treatment of hypoxemia |
| GB202006659D0 (en) * | 2020-05-05 | 2020-06-17 | Wista Lab Ltd | Therapeutic treatments |
| EP4531863A1 (en) | 2022-05-31 | 2025-04-09 | WisTa Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| EP4342451A1 (en) * | 2022-09-22 | 2024-03-27 | Galenicum Health SLU | Pharmaceutical compositions and manufacturing methods thereof |
| US20240115579A1 (en) * | 2022-09-22 | 2024-04-11 | Galenicum Health S.L.U. | Pharmaceutical compositions and manufacturing methods thereof |
| EP4651874A2 (en) * | 2023-02-21 | 2025-11-26 | Prosetta Biosciences, Inc. | Phenothiazinyl compounds and uses |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| PL373903A1 (en) | 2002-05-31 | 2005-09-19 | H.Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| AU2005286235C1 (en) | 2004-09-23 | 2013-08-22 | TauRx Therapeutics Management Ltd | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including Methylthioninium Chloride (MTC) |
| PT2013191E (pt) | 2006-03-29 | 2010-10-29 | Wista Lab Ltd | Sais de 3,7-diamino-10h-fenotiazina e a sua utilização |
| MY162640A (en) | 2006-03-29 | 2017-06-30 | Wista Lab Ltd | Thioninium compounds and their use |
| FR2899107B1 (fr) * | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | Utilisation de la (s)-roscovitine pour la fabrication d'un medicament |
| MY148145A (en) | 2006-07-11 | 2013-03-15 | Wista Lab Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| FR2903696B1 (fr) | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
| US9034890B2 (en) * | 2006-11-15 | 2015-05-19 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
| SI2167095T1 (sl) | 2007-06-19 | 2019-09-30 | Wista Laboratories Ltd. | Fenotiazinske spojine za zdravljenje blage kognitivne motnje |
| PL2205245T3 (pl) * | 2007-10-03 | 2015-12-31 | Wista Lab Ltd | Zastosowanie terapeutyczne diaminofenotiazyn |
| AU2010299571B2 (en) | 2009-09-24 | 2014-07-31 | TauRx Therapeutics Management Ltd | Crystalline methylthionium chloride (methylene blue) hydrates |
| MY161463A (en) | 2009-09-24 | 2017-04-14 | Wista Lab Ltd | Process for the preparation of substantially pure methylthionium chloride pentahydrate form a |
| DK2673266T3 (en) * | 2011-02-11 | 2016-10-24 | Wista Lab Ltd | Phenothiazine DIAMINIUM SALTS AND USE THEREOF |
| CN102936244B (zh) * | 2012-12-04 | 2015-02-04 | 合肥工业大学 | 一种他克林-吩噻嗪异二联体类化合物及其制备方法 |
-
2016
- 2016-09-01 GB GBGB1614834.8A patent/GB201614834D0/en not_active Ceased
-
2017
- 2017-08-25 SG SG11201901125TA patent/SG11201901125TA/en unknown
- 2017-08-25 JP JP2019511720A patent/JP7066679B2/ja active Active
- 2017-08-25 WO PCT/EP2017/071437 patent/WO2018041739A1/en not_active Ceased
- 2017-08-25 CN CN201780067154.4A patent/CN109890391B/zh active Active
- 2017-08-25 SI SI201730630T patent/SI3506904T1/sl unknown
- 2017-08-25 DK DK17761842.8T patent/DK3506904T3/da active
- 2017-08-25 EP EP17761842.8A patent/EP3506904B1/en active Active
- 2017-08-25 PT PT177618428T patent/PT3506904T/pt unknown
- 2017-08-25 MY MYPI2019001119A patent/MY187564A/en unknown
- 2017-08-25 KR KR1020197009175A patent/KR102559354B1/ko active Active
- 2017-08-25 PL PL17761842T patent/PL3506904T3/pl unknown
- 2017-08-25 HR HRP20210162TT patent/HRP20210162T1/hr unknown
- 2017-08-25 US US16/329,611 patent/US10842796B2/en active Active
- 2017-08-25 CA CA3034625A patent/CA3034625A1/en active Pending
- 2017-08-25 ES ES17761842T patent/ES2847929T3/es active Active
- 2017-08-25 MX MX2019002429A patent/MX384442B/es unknown
- 2017-08-25 AU AU2017318333A patent/AU2017318333B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526571A5 (enExample) | ||
| JP6795517B2 (ja) | ５−芳香族アルキニル基置換ベンズアミド系化合物並びにその製造方法、薬物組成物及び使用 | |
| AU2014368961B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| EP3606525B1 (en) | Compositions for treating aging-associated impairments using ccr3-inhibitors | |
| JP7514534B2 (ja) | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 | |
| HRP20210162T1 (hr) | Liječenje demencije | |
| JP2015532295A5 (enExample) | ||
| JP2021503480A (ja) | トラジピタントを用いた胃腸疾患の治療方法 | |
| EP3555100A1 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| JP2019521964A5 (enExample) | ||
| CN102753172A (zh) | 用于治疗痴呆的5-ht4受体激动剂 | |
| JP2023534189A (ja) | Ｇａｂａａアルファ５アゴニストおよびｓｖ２ａ阻害剤の組合せ物ならびに認知障害の処置において使用する方法 | |
| BRPI0808353B1 (pt) | Usos de amidas do ácido 3-aril-3-hidróxi-2-amino-propiônico, amidas do ácido 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados | |
| US8598180B2 (en) | Tetrahydroindolone derivatives for treatment of neurological conditions | |
| JP2019518736A5 (enExample) | ||
| CN107709326A (zh) | 降低应激诱导的p‑tau的三唑并吡啶和三唑并嘧啶 | |
| JP7090344B2 (ja) | セロトニン３受容体アゴニストによる疼痛の治療 | |
| BR112021004938A2 (pt) | métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3 | |
| WO2016006621A1 (ja) | Ｐｇｄ２拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬 | |
| US20090156609A1 (en) | Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperzaine compounds | |
| JPWO2004063201A1 (ja) | 統合失調症治療剤 | |
| JP2010530900A (ja) | 中枢神経系活性を有する置換ピロリジン化合物 | |
| HK40092010A (zh) | GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法 | |
| JP2011020957A (ja) | アルツハイマー病治療薬 | |
| US20100227844A1 (en) | Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease |